Revolution Medicines Inc
RVMD
Company Profile
Business description
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Contact
700 Saginaw Drive
Redwood CityCA94063
USAT: +1 650 481-6801
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
809
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Our view of the proposed merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,326.10 | 74.60 | -0.79% |
| CAC 40 | 8,394.32 | 186.43 | -2.17% |
| DAX 40 | 24,638.00 | 646.26 | -2.56% |
| Dow JONES (US) | 48,838.69 | 139.23 | -0.28% |
| FTSE 100 | 10,780.11 | 130.44 | -1.20% |
| HKSE | 26,127.36 | 67.51 | 0.26% |
| NASDAQ | 22,706.85 | 38.64 | 0.17% |
| Nikkei 225 | 57,369.87 | 687.37 | -1.18% |
| NZX 50 Index | 13,629.47 | 93.50 | -0.68% |
| S&P 500 | 6,875.63 | 3.25 | -0.05% |
| S&P/ASX 200 | 9,102.90 | 65.20 | -0.71% |
| SSE Composite Index | 4,193.66 | 11.07 | 0.26% |